Biocon Biologics is a unique, fully integrated leading global biosimilars player that is driven by an unwavering purpose to enable equitable access to high-quality, lifesaving biosimilars for patients globally.

Biocon Biologics is an end-to-end biosimilars enterprise with established capabilities in the development, manufacturing and commercialization of high-quality biosimilars. The company is leveraging cutting-edge science, advanced R&D skills, innovative tech platforms, global-scale manufacturing capabilities and internationally benchmarked quality and regulatory systems to address the global need for essential medicines to treat chronic diseases. Eight of its biosimilars, including insulins and antibodies, have been commercialized and are benefiting ~5.7 million patients annually in more than 100 countries.

As an industry pioneer, Biocon Biologics is among the first wave of companies to commercialize multiple biosimilars in the U.S., Europe and several other advanced and emerging market countries. These include Trastuzumab, Bevacizumab and Pegfilgrastim for cancer; Insulin Glargine, Insulin Aspart and recombinant human Insulin for diabetes, and Adalimumab and Etanercept for autoimmune diseases.

A frontrunner in the global biosimilars industry, Biocon Biologics has invested over USD 1 billion in building dedicated ‘lab to market’ capabilities for biosimilars. This has led to the creation of two state-of-the-art R&D facilities in India and three large-scale, globally compliant manufacturing facilities in India and Malaysia. The company has also invested in best-in-class quality processes and technology to meet the most stringent quality standards and successfully gain regulatory approvals in several jurisdictions, including U.S., EU, Australia, Canada and Japan. Biocon Biologics has achieved many global ‘firsts,’ including the industry’s first approval of an interchangeable biosimilar for Insulin Glargine in the U.S. It is also the first globally to receive approvals for biosimilar Trastuzumab and biosimilar Pegfilgrastim from the U.S. Food and Drug Administration (FDA).

The company has been able to establish brand equity with patients, prescribers, payors and regulators through an impeccable track record of quality, safety, and reliability.
To strengthen its leadership position in the global biosimilars industry, Biocon Biologics has acquired the global biosimilars business of its long-term partner Viatris for over USD 3 billion in cash and stock. This is a historic milestone in the company’s value creation journey and brings it closer to patients, customers, and payors in several advanced and emerging market countries.

By combining the complementary capabilities and strengths of two long-term partners, it is leveraging THE POWER OF ONE with an aim to reduce healthcare inequities and transform healthcare, worldwide.

Biocon Biologics is well-positioned for future growth with its comprehensive portfolio of 20 biosimilars for diabetes, cancer, autoimmune diseases, ophthalmic conditions and bone health.

Environmental, Social and Governance (ESG) is at the core of Biocon Biologics’ business purpose and responsibility. The company’s philosophy of unconditional equity aims to ensure the well-being of patients, people, partners, customers, shareholders, communities and the ecosystem at large. By serving patients, protecting the environment and promoting business integrity, the company is taking ‘sustainable action’ every day, reinforcing its commitment to building an equitable and viable future.

Biocon Biologics Limited
Biocon House, Semicon Park, Electronics City, Phase - II, Hosur Road, Bengaluru, Karnataka 560 100. India. T: +91 80 6775 6775.
Email: Group.Comunications@biocon.com
Website: www.bioconbiologics.com
Follow us at: ☏️ @ 🌐

Note: The information in this Fact Sheet is given as of the date mentioned, and Biocon Biologics does not assume any obligation to update the information on a frequent basis.

Last Updated: August 04, 2023